Since 2016, insurance companies in the European Union have to comply with Solvency II regulation. This Directive imposes equity solvency capital requirements. This means that insurance companies have to hold a capital buffer to survive adverse shocks in financial markets. Most European pension funds are still subject to local regulation, but these local frameworks tend to resemble Solvency II.
Under Solvency II the standard solvency capital requirement (SCR) for a diversified equity portfolio is 39% for stocks listed in developed markets and 49% for those listed in emerging markets. This SCR is adjusted up or down with a maximum of 10 percentage points, depending on the equity market’s past three-year performance. The equity SCR is intended as a means to keep the probability of bankruptcy over the next twelve months below 0.5%.
Solvency II has a different equity solvency capital requirement for developed market stocks (39%) percent) and emerging market stocks (49%). This makes sense, as there is a difference in financial economic risk between the two types of markets. However, differences in financial economic risk within developed or emerging markets are not taken into account. This has two unintended, potentially detrimental consequences:
We will explain why. First of all, within developed or within emerging equity markets, the risk of each equity portfolio is assumed to be the same. If you assume that more risk should lead to more return, this regulation creates an incentive to buy more risky stocks. This can be seen in Figure 1, where we depict a low-risk (blue) and a high-risk (red) portfolio. Solvency II assumes the risk for each of these two portfolios to be the same as the market’s, as indicated by the blue and red circles. As a result, the Solvency II investor does not face a risk-return trade-off, but can choose the highest return regardless of financial economic risk. Instead of promoting prudency, Solvency II therefore encourages risk-seeking behavior.
This is linked to the second unintended consequence of Solvency II. If large enough pools of capital are exposed to Solvency II-type regulation, the price of high-risk stocks is driven up more than warranted by their economic risk, while the price of low-risk stocks is pushed down more than justified by their economic risk. This leads to lower future returns for high-risk stocks, and higher future returns for low-risk stocks. Investors only have an incentive to buy the low-risk stocks when their price has decreased so much that the relation between risk and return has become flat or inverse. Such a distortion between risk and return is indeed observed in practice, and is commonly referred to as the low-risk anomaly. Oversimplified regulation such as the crude Solvency II SCR framework may help create and sustain this anomaly.
We urge European regulators for institutional investors to improve Solvency II by aligning it with more sophisticated European regulation that is already in place for private investors in mutual funds. This would reduce the potential harmful unintended consequences from existing solvency regulation.
Specifically, we propose to multiply the standard solvency charge of 39% with the ratio of the company’s equity portfolio volatility to the broad equity market’s volatility. This is a way to capture a portfolio’s relative risk. The ratio will be above one for more risky portfolios and below one for less risky portfolios, meaning that high-risk stock portfolios require more solvency capital than the market, and low-risk stock portfolios less. In our proposal the distinction between developed (SCR of 39%) and emerging (SCR of 49%) stocks has disappeared. This is because our formula already accounts for this difference.
For the broad equity market we propose to use the MSCI World Index. For volatility, we propose to take the five-year volatility and review this on a quarterly basis. If the company’s equity strategy does not have a representative five-year history, we propose backfilling the equity return history with a representative alternative proxy return series, such as an index that follows a similar investment strategy.
Our proposed approach encompasses the existing distinction between emerging and developed markets, and also takes into account many other potential sources of risk. It is a straightforward and cost-efficient way for asset owners to assess risk, which is already used in regulation for European retail investors. It gives better incentives to institutional investors, contributes to market efficiency and is difficult to manipulate. In short, it reduces potentially harmful, unintended consequences of existing regulation for institutional investors.
The content displayed on this website is exclusively directed at qualified investors, as defined in the swiss collective investment schemes act of 23 june 2006 ("cisa") and its implementing ordinance, or at “independent asset managers” which meet additional requirements as set out below. Qualified investors are in particular regulated financial intermediaries such as banks, securities dealers, fund management companies and asset managers of collective investment schemes and central banks, regulated insurance companies, public entities and retirement benefits institutions with professional treasury or companies with professional treasury.
The contents, however, are not intended for non-qualified investors. By clicking "I agree" below, you confirm and acknowledge that you act in your capacity as qualified investor pursuant to CISA or as an “independent asset manager” who meets the additional requirements set out hereafter. In the event that you are an "independent asset manager" who meets all the requirements set out in Art. 3 para. 2 let. c) CISA in conjunction with Art. 3 CISO, by clicking "I Agree" below you confirm that you will use the content of this website only for those of your clients which are qualified investors pursuant to CISA.
Representative in Switzerland of the foreign funds registered with the Swiss Financial Market Supervisory Authority ("FINMA") for distribution in or from Switzerland to non-qualified investors is Robeco Switzerland AG, Josefstrasse 218, 8005 Zürich, and the paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zürich. Please consult www.finma.ch for a list of FINMA registered funds.
Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco/Robeco Switzerland product should only be made after reading the related legal documents such as management regulations, articles of association, prospectuses, key investor information documents and annual and semi-annual reports, which can be all be obtained free of charge at this website, at the registered seat of the representative in Switzerland, as well as at the Robeco/Robeco Switzerland offices in each country where Robeco has a presence. In respect of the funds distributed in Switzerland, the place of performance and jurisdiction is the registered office of the representative in Switzerland.
This website is not directed to any person in any jurisdiction where, by reason of that person's nationality, residence or otherwise, the publication or availability of this website is prohibited. Persons in respect of whom such prohibitions apply must not access this website.